Key clinical point: A new and simple model for predicting risk of severe neutropenia in advanced lung cancer could ease the evaluation process and help inform patient management decisions.
Major finding: The area under the curve (AUC) in the training and testing set was 0.8348 and 0.8234, respectively.
Study details: Development and validation of a risk prediction model based on a lung cancer data set including 11,352 patients from 67 phase 2 or 3 studies.
Disclosures: The study was supported in part by grants from the National Institutes of Health, the National Center for Advancing Translational Sciences, and the Health and Medical Research Fund of Hong Kong. One study coauthor reported a conflict of interest outside the submitted work related to Genentech.
Cao X et al. Lung Cancer. 2020 Jan 5. doi: 10.1016/j.lungcan.2020.01.004.